Guided Therapeutics Inc  

(Public, OTCBB:GTHP)   Watch this stock  
Find more results for OTC:GTHP
0.0000 (0.00%)
May 2 - Close
OTCBB data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.05 - 19.00
Open     -
Vol / Avg. 0.00/246,895.00
Mkt cap 237,069.00
P/E     -
Div/yield     -
EPS -7.20
Shares 4.81M
Beta 0.14
Inst. own 0%
May 11, 2016
Q1 2016 Guided Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 15, 2016
Q4 2015 Guided Therapeutics Inc Earnings Call
Mar 14, 2016
Q4 2015 Guided Therapeutics Inc Earnings Release

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -703.20% -1138.94%
Operating margin -617.60% -1027.56%
EBITD margin - -853.63%
Return on average assets -264.59% -246.76%
Return on average equity - -
Employees 33 -
CDP Score - -


5835 Peachtree Cors E Ste D
NORCROSS, GA 30092-3413
United States - Map
+1-770-2428723 (Phone)
+1-770-2428639 (Fax)

Website links


Guided Therapeutics, Inc. is a medical technology company focused on developing medical devices. The Company's focus is the sales and marketing of its LuViva Advanced Cervical Scan. LuViva is a non-invasive cervical cancer detection product, based on the Company's biophotonic technology. The device is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point-of-care by scanning the cervix with light, then analyzing the light reflected or emanating from the cervix. The information presented by the light is used to indicate the likelihood of cervical cancer or precancers. LuViva is also designed to detect the biochemical changes that precede the development of visual lesions. It has approval to sell the product LuViva in Canada, Mexico, Singapore, the European Union and additional countries. It has completed the pivotal trial for LuViva and has filed its premarket approval (PMA) application with the United States Food and Drug Administration (FDA).

Officers and directors

Michael C. James Independent Chairman and Director
Age: 57
Gene S. Cartwright Ph.D. Chief Executive Officer, Acting Chief Financial Officer, President and Director
Age: 61
Richard L. Fowler Senior Vice President - Engineering
Age: 58
John E. Imhoff M.D. Independent Director
Age: 66
Jonathan M. Niloff M.D. Independent Director
Age: 61
Linda M. Rosenstock M.D. Independent Director
Age: 64